Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

Go back to Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
Regeneron (NASDAQ: REGN) Delayed: 801.76 -5.72 (0.71%)
Previous Close $807.48    52 Week High $592.36 
Open $806.74    52 Week Low $325.35 
Day High $813.86    P/E 210.44 
Day Low $800.24    EPS $3.81 
Volume 250,166